4 research outputs found
Recommended from our members
Rates of lobar atrophy in asymptomatic MAPT mutation carriers.
IntroductionThe aim of this study was to investigate the rates of lobar atrophy in the asymptomatic microtubule-associated protein tau (MAPT) mutation carriers.MethodsMAPT mutation carriers (n = 14; 10 asymptomatic, 4 converters from asymptomatic to symptomatic) and noncarriers (n = 13) underwent structural magnetic resonance imaging and were followed annually with a median of 9.2 years. Longitudinal changes in lobar atrophy were analyzed using the tensor-based morphometry with symmetric normalization algorithm.ResultsThe rate of temporal lobe atrophy in asymptomatic MAPT mutation carriers was faster than that in noncarriers. Although the greatest rate of atrophy was observed in the temporal lobe in converters, they also had increased atrophy rates in the frontal and parietal lobes compared to noncarriers.DiscussionAccelerated decline in temporal lobe volume occurs in asymptomatic MAPT mutation carriers followed by the frontal and parietal lobe in those who have become symptomatic. The findings have implications for monitoring the progression of neurodegeneration during clinical trials in asymptomatic MAPT mutation carriers
A Wide and Deep Neural Network for Survival Analysis from Anatomical Shape and Tabular Clinical Data
We introduce a wide and deep neural network for prediction of progression
from patients with mild cognitive impairment to Alzheimer's disease.
Information from anatomical shape and tabular clinical data (demographics,
biomarkers) are fused in a single neural network. The network is invariant to
shape transformations and avoids the need to identify point correspondences
between shapes. To account for right censored time-to-event data, i.e., when it
is only known that a patient did not develop Alzheimer's disease up to a
particular time point, we employ a loss commonly used in survival analysis. Our
network is trained end-to-end to combine information from a patient's
hippocampus shape and clinical biomarkers. Our experiments on data from the
Alzheimer's Disease Neuroimaging Initiative demonstrate that our proposed model
is able to learn a shape descriptor that augments clinical biomarkers and
outperforms a deep neural network on shape alone and a linear model on common
clinical biomarkers.Comment: Data and Machine Learning Advances with Multiple Views Workshop,
ECML-PKDD 201
MODELING ALZHEIMER'S DISEASE PROGRESSION ON A PATHOLOGICAL TIMELINE
Ph.DDOCTOR OF PHILOSOPH